Lyme disease | HealthCare Africa Magazine

Pfizer-Valneva Lyme vaccine poised for phase 3 trials

8 February 20228 February 2022

USA – Pfizer Inc. and Valneva SE, have announced additional positive Phase 2 data for their Lyme disease vaccine candidate, VLA15, the only Lyme disease vaccine candidate currently in clinical…

Valneva, Pfizer set to rollout phase 2 trials of its Lyme disease vaccine candidate

19 July 202121 July 2021

WORLD – Valneva, a specialty vaccine company for infectious diseases, and Pfizer, have completed their recruitment for the phase 2 trials, VLA15-221, of Lyme disease vaccine candidate, VLA15. The trial…